medigraphic.com
ISSN 1561-297X (Print)

2015, Number 4

<< Back Next >>

Rev Cubana Estomatol 2015; 52 (4)

Oral manifestations in patients undergoing chemotherapy

Campos ATL, Martins MLK, Mendonça VR, Nobre MAKM, do Amaral RC, Fonseca ST

Language: Portugués
References: 33
Page: 16-21
PDF size: 265.18 Kb.


ABSTRACT

Introduction: chemotherapy is a treatment based on the use of anticancer drugs that induce the death of cancer cells. The literature describes oral lesions may arise as a result of chemotherapy. Objective: to identify the oral manifestations in patients undergoing chemotherapy treated at the reference service in oncology southern state of Ceará-Brazil. Methods: we evaluated 73 patients affected by some type of malignancy and chemotherapy from January of 2013 to December of 2014. The clinical and pathological data such as age, gender, diagnosis of malignancy, types of treatments anticancer chemotherapeutic drug treatment, among others,were obtained from medical records. Were also carried out oral examinations in all subjects of this study by the same examiner specialist in stomatology. Results: of the 73 patients 29 (39.7 %) were male and 44 (60.3 %) females with a mean age of 57.7 years, and 37 (50.7 %) of smokers. Regarding malignancy, the mama was the most prevalent location (35.6 %). The drugs most frequently used in chemotherapy treatment were aredia in 23.3 % of cases (n= 17) and paclitaxel in 17.8 % (n= 13). In the oral manifestations, of the 73 patients studied, 44 (60.2 %) had some type of oral discomfort. Most patients, 77.3 % (n= 34) were diagnosed with xerostomia and 22.7 % (n= 10) were observed mucositis. Conclusion: oral lesions found in patients undergoing chemotherapy were xerostomia and mucositis. Xerostomia being the most prevalent oral pathological condition.


REFERENCES

  1. Facina T. Estimativa 2014 – Incidência de Câncer no Brasil. Rev Brasil Cancer. 2014;60(1):63-4.

  2. Islam F, Qiao RA, Smith V, Lam AK. Cancer stem cell: Fundamental experimental pathological concepts and updates. Exp Mol Pathol. 2015;98(2):184-91.

  3. Fonseca-Silva T, Farias LC, Cardoso CM, Souza LR, Fraga CA, Oliveira MV, et al. Analysis of p16(CDKN2A) methylation and HPV-16 infection in oral mucosal dysplasia. Pathobiology. 2012;79(2):94-100.

  4. Jimenez-Ballve A, Serrano-Palacio A, Garcia-Saenz JA, Ortega CA, Salsidua-Arroyo O, Roman-Santamaria JM, et al. Axillary pathologic response after neoadjuvant chemotherapy in locally advanced breast cancer with axillary involvement. Rev Esp Med Nucl Imagen Mol. 2015;1(1):1-6.

  5. Park WY, Kim HJ, Kim K, Bae SB, Lee N, Lee KT, et al. Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis. Cancer Res Treat. 2015;1(1):1-11.

  6. DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643-53.

  7. Martins ACM, Caçador NP, Gaeti WP. Complicações bucais da quimioterapia antineoplásica. Acta Scientiarum. 2002;24(3):663-70.

  8. Xu L, Zhang H, Liu J, Chen X. Investigation of the oral infections and manifestations seen in patients with advanced cancer. Pak J Med Sci. 2013;29(5):1112-5.

  9. Freedman OC, Fletcher GG, Gandhi S, Mates M, Dent SF, Trudeau ME, et al. Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol. 2015;22(Suppl 1):95-113.

  10. Lorusso D, Petrelli F, Coinu A, Raspagliesi A, Barni S. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol. 2014;133(1):117-23.

  11. Toscano N, Holtzclaw D, Hargitai IA, Shumaker N, Richardson H, Naylor G, et al. Oral implications of cancer chemotherapy. J Implant & Advanced Clinical Dentistry. 2009;1(5):52-67.

  12. Morais EF, Lira JA, Macedo RA, Santos KS, Elias CT, Morais L. Oral manifestations resulting from chemotherapy in children with acute lymphoblastic leukemia. Braz J Otorhinolaryngol. 2014;80(1):78-85.

  13. Epstein JB, Tsang AH, Warkentin D, Ship JA. The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;94(1):39-44.

  14. Parkhill AL. Oral Mucositis and Stomatitis Associated with Conventional and Targeted Anticancer Therapy. J Pharmacovigilance. 2013;1(4):1-4.

  15. Bey A, Ahmed SS, Hussain B, Devi S, Hashmi SH. Prevention and management of antineoplastic therapy induced oral mucositis. Natl J Maxillofac Surg. 2010;1(2):127-34.

  16. Hespanhol FL, Tinoco EMB, Teixeira HGC, Falabella MEV, Assis NMS. Manifestações bucais em pacientes submetidos à quimioterapia. Ciência & Saúde Coletiva. 2010;15(1):1085-94.

  17. Bensadoun RJ, Magne N, Marcy PY, Demard F. Chemotherapy and radiotherapy induced mucositis in head and neck cancer patients: new trends in pathophysiology, prevention and treatment. Eur Arch Otorhinolaryngol. 2001; 258(9):481-7.

  18. Jensen SB, Mouridsen HT, Reibel J, Brunner N, Nauntofte B. Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction. Oral Oncol. 2008;44(2):162-73.

  19. Pow EH, McMillan AS, Leung WK, Wong MC, Kwong DL. Salivary gland function and xerostomia in southern Chinese following radiotherapy for nasopharyngeal carcinoma. Clin Oral Investig. 2003;7(4):230-4.

  20. Mravak-Stipetić M. Xerostomia - diagnosis and treatment. Medical Sciences. 2012;38(1):69-91.

  21. Huber MA, Terezhalmy GT. The medical oncology patient. Quintessence Int. 2005;36(5):383-402.

  22. Nicolatou-Galitis O, Kouloulias V, Sotiropoulou-Lountou A, Dardoufas A, Polychronopoulou A, Athanassiadou P, et al. Oral mucositis, pain and xerostomia in 135 head and neck cancer patients receiving radiotherapy with or without chemotherapy. The Open Cancer Journal. 2011;4:7-17.

  23. Turner MD, Ship JA. Dry mouth and its effects on the oral health of elderly people. J Am Dent Assoc. 2007;138 (Suppl):15-20.

  24. Porter SR, Scully C, Hegarty AM. An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97(1):28-46.

  25. Aguilar-Ponce JL, Granados-Garcia M, Cruz Lopez JC, Maldonado-Magos F, Alvarez-Avitia MA, Arrieta O, et al. Alternating chemotherapy: gemcitabine and cisplatin with concurrent radiotherapy for treatment of advanced head and neck cancer. Oral Oncol. 2013;49(3):249-54.

  26. Focazio B. Clinical snapshot: mucositis. Am J Nurs. 1997;97(12):48-9.

  27. McCarthy GM, Awde JD, Ghandi H, Vincent M, Kocha WI. Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. Oral Oncol. 1998;34(6):484-90.

  28. Fekrazad R, Chiniforush N. Oral mucositis prevention and management by therapeutic laser in head and neck cancers. J Lasers Med Sci. 2014;5(1):1-7.

  29. Raber-Durlacher JE, Elad S, Barasch A. Oral mucositis. Oral Oncol. 2010;46(6):452-6.

  30. Skeff MA, Brito GA, Oliveira MG, Braga CM, Cavalcante MM, Baldim V, et al. S-nitrosoglutathione accelerates recovery from 5-Fluorouracil-induced oral mucositis. PLoS One. 2014;9(12):e113378.

  31. Zur E. Oral mucositis: etiology, and clinical and pharmaceutical management. Int J Pharm Compd. 2012;16(1):22-33.

  32. Lalla RV, Saunders DP, Peterson DE. Chemotherapy or radiation-induced oral mucositis. Dent Clin North Am. 2014;58(2):341-9.

  33. Ottaviani G, Gobbo M, Sturnega M, Martinelli V, Mano M, Zanconati F, et al. Effect of class IV laser therapy on chemotherapy-induced oral mucositis: a clinical and experimental study. Am J Pathol. 2013;183(6):1747-57.




2020     |     www.medigraphic.com